{"id":380165,"date":"2020-11-12T15:59:38","date_gmt":"2020-11-12T20:59:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380165"},"modified":"2020-11-12T15:59:38","modified_gmt":"2020-11-12T20:59:38","slug":"important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/","title":{"rendered":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc."},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ShyWahrMnW6o4eUubX00T1NMbwXgqlKcbjNbtFtk6luhgVqWggN6h1VRBag7kwjucuBJvbNFgZcmbVUiDl6IdrYlpt2nui4UPe7EYfi8SGfdEIAaIfGAnhZrvziRNd1VADmRlokQOn-s869w1a268g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L27PJd8CGd_zz6Fv5--PRwWGYrpvW80juqaWrPaDDxQpTmvO0wrkz_ngPtkVxhO4PJ4kArHIPEwZQ2UzsKRcRLZXWA9NdybkhI1lEPHDzwg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1\/2 study to support valoctocogene roxaparvovec\u2019s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration (\u201cFDA\u201d) would not approve the Biologics License Application (\u201cBLA\u201d) for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/>info@pawarlawgroup.com\u00a0\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380165","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the &hellip; Continue reading &quot;IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T20:59:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.\",\"datePublished\":\"2020-11-12T20:59:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/\"},\"wordCount\":349,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/\",\"name\":\"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\",\"datePublished\":\"2020-11-12T20:59:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/","og_locale":"en_US","og_type":"article","og_title":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk","og_description":"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the &hellip; Continue reading \"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T20:59:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.","datePublished":"2020-11-12T20:59:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/"},"wordCount":349,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/","name":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN - Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=","datePublished":"2020-11-12T20:59:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMyNCMzODI1MTU5IzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-nov-24-deadline-bmrn-pawar-law-group-announces-a-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMPORTANT NOV. 24 DEADLINE \u2013 BMRN &#8211; Pawar Law Group Announces a Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380165"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380165\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}